An improved comorbidity index for outcome analyses among dialysis patients  by Liu, Jiannong et al.
see commentary on page 83
An improved comorbidity index for outcome
analyses among dialysis patients
Jiannong Liu1, Zhi Huang1,2, David T. Gilbertson1, Robert N. Foley1,3 and Allan J. Collins1,3
1United States Renal Data System, Minneapolis, Minnesota, USA; 2Clinical Statistics, GPRD, Abbott Laboratories, Abbott Park, Illinois,
USA and 3Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
Since comorbid conditions are highly prevalent among
patients with end-stage renal disease, indexes measuring
them have been widely used to describe the comorbidity
burden and to predict outcomes as well as adjust for their
roles as confounders. The current comorbidity indexes,
however, were developed for general populations or on
small patient cohorts. In this study we developed a new index
for mortality analyses of dialysis patients based on the 2000
US incident dialysis population, and validated this using the
1999 and 2001 incident and 2000 prevalent dialysis patient
populations. Numerical weights were assigned to the
comorbid conditions of atherosclerotic heart disease,
congestive heart failure, cerebrovascular accident/transient
ischemic attack, peripheral vascular disease, dysrhythmia,
other cardiac diseases, chronic obstructive pulmonary
disease, gastrointestinal bleeding, liver disease, cancer, and
diabetes. A patient’s comorbidity score was the sum of the
weights corresponding to the individual conditions present
and could be used as a continuous variable in analyses. Our
index performance was almost identical to the individual
comorbid conditions regarding model fit, predictive ability,
and effect on inference, and it outperformed the widely used
Charlson Comorbidity Index.
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Comorbid conditions are highly prevalent among end-stage
renal disease (ESRD) patients, and comorbidity indexes have
been widely used for describing comorbidity burden, predicting
outcomes, and adjusting as a confounder in analyses involving
ESRD patients.1–4 A comorbidity index can give a single-value
summary for several comorbid conditions, thereby simplifying
the comparison. A comorbidity index can also reduce the
dimension of model-based analysis. Too many comorbid
conditions and their correlations may distort the information
an analysis yields. Large numbers of variables and their
correlations may also make the parameter estimation inefficient
and the result difficult to interpret.5 Reducing the dimension of
the analysis and therefore reducing the correlations among
variables is necessary to produce reliable and meaningful
results, especially when the sample size is small.
Several comorbidity indexes have been used for analysis of
ESRD patients. The Charlson Comorbidity Index (CCI)6 is
the most widely used. It was developed for mortality analysis
based on 604 patients admitted to the medical services at
New York Hospital-Cornell Medical Center during a
1-month period in 1984, and was validated based on 685
women with histologically proven primary carcinoma of the
breast, who received their first treatment at Yale New Haven
Hospital between 1 January 1962 and 31 December 1969.
Khan et al.7 proposed a comorbidity index for survival
analysis based on 375 ESRD patients, and Davies et al.8 used a
different comorbidity index for analyses of 97 continuous
ambulatory peritoneal dialysis patients. Van Manen et al.9
compared these three indexes and showed that the CCI
performs slightly better than the other two, based on
c-statistic, a model predictive ability statistic.10 Fried et al.3
compared the CCI with the Davies comorbidity index based
on 415 incident peritoneal dialysis patients. Results showed
that CCI was a better predictor for mortality, but the Davies
index was a better predictor for hospitalizations.
These comorbidity indexes were developed for general
populations or on small samples. The effects on survival of
the comorbid conditions included in the CCI are different for
the general population than for ESRD patients.11 Whether
the CCI conditions can accurately describe the comorbidity
burden for ESRD patients is also questionable. The Khan
index did not specify which conditions should be included,
and mixed chronological age with comorbid conditions
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without showing clear evidence for doing so. In the Davies
index, all comorbid conditions were assigned the same
weight no matter how different their effects on outcome, and
the definitions of the conditions were unclear.
In addition, these indexes were not formally validated or
were validated based only on predictive ability or significance
as a predictor. The validation of an index should be goal-
driven, against a gold standard. To be used to predict
mortality, a comorbidity index should have the same, or very
similar, predictive ability for mortality as the individual
comorbid conditions represented by the index. To be used as
an adjustor in survival analyses, a comorbidity index should
make the same inferences made when using individual
comorbid conditions. An index validated for mortality
prediction should not be used for medical cost prediction,
unless it was also validated for doing so.
Increasing numbers of analyses are done using adminis-
trative data. In addition to observational studies, some clinical
trials12,13 and ‘quasi-clinical trials’14 are conducted based at
least partially on the Centers for Medicare & Medicaid (CMS)
ESRD database, which is the largest administrative database for
ESRD patients in the United States. For those studies, most
information on comorbid conditions was derived from the
CMS ESRD database. A comorbidity index developed for
analyses based on administrative data would be useful. Thus,
we propose a new comorbidity index, including and excluding
ESRD primary cause, for mortality analyses of dialysis patients,
using administrative data, based on the comorbid conditions
used by the United States Renal Data System (USRDS).15 The
index was developed using the 2000 US incident dialysis
population and validated using the 1999 and 2001 US incident
dialysis populations and the 2000 US prevalent dialysis
population. The validation was based on model fit, model
predictive ability, index predictive ability, and effect on
inference. The new index was also checked to see if it can be
used for hospitalization and medical cost analysis. Because the
CCI performs better than the other indexes for mortality
analyses among dialysis patients,3,9 the new index was
compared with it.
RESULTS
Description of data
A total of 102,134 incident and 142,517 prevalent dialysis
patients were included in this study (Table 1). Mean follow-
up time was 2.3 years per patient for incident and 2.5 years
per patient for prevalent patients. Percentages of patients
with atherosclerotic heart disease (ASHD), congestive heart
failure (CHF), cerebrovascular accident/transient ischemic
attack (CVA/TIA), chronic obstructive pulmonary disease
(COPD), dysrhythmia, diabetes and liver disease increased
over the incident year. Compared with the incident cohort,
prevalent patients were younger, fewer were white, fewer had
diabetes as primary ESRD cause, and fewer had comorbid
conditions, possibly because of older patients with more
comorbidity dying earlier than younger, healthier patients.
The death rate was 26.36, 26.21, 25.59, and 24.55 per 100
patient-years for the 1999, 2000, 2001 incident cohorts and
the 2000 prevalent cohort, respectively. It decreased slightly
over time for incident patients.
Calculation of comorbidity score
The coefficient estimates and their P-values for all variables
from the Cox proportional regression model for the 2000
Table 1 | Patient characteristics: 1999–2001 US incident
dialysis patients and 2000 prevalent dialysis patients
Cohorta
1999
Incident
2000
Incident
2001
Incident
2000
Prevalent
Characteristics n=33,166 n=33,077 n=35,891 n=142,517
Age
Mean 65.6 65.0 66.0 61.0
Median 69.0 68.0 69.0 63.0
s.d. 14.7 15.0 15.0 16.0
Age group, years
0–19 0.3 0.4 0.4 0.4
20–29 1.9 2.1 1.9 3.0
30–39 4.6 4.6 4.4 7.5
40–49 8.4 9.0 8.2 13.7
50–59 13.6 13.7 13.5 18.2
60–64 8.3 8.9 8.9 10.1
65–69 15.4 14.5 15.0 12.7
70–79 33.0 32.1 32.1 24.9
X80 14.6 14.8 15.6 9.7
Sex
Women 48.3 48.1 48.0 48.3
Men 51.7 51.9 52.0 51.7
Race
White 64.0 64.1 65.4 52.9
African American 30.7 30.8 29.8 41.7
Native American 1.6 1.6 1.4 1.6
Asian 2.8 2.7 2.6 3.1
Other 0.8 0.9 0.8 0.7
ESRD primary cause
Diabetes 46.9 47.5 48.4 38.6
Hypertension 29.8 29.7 29.4 29.9
Glomerulonephritis/
cystic kidney disease
10.4 9.6 9.2 17.4
Other 12.9 13.2 13.1 14.1
Comorbid conditions
ASHD 51.5 52.2 53.8 41.2
CHF 54.3 55.0 55.5 44.3
CVA/TIA 24.2 25.1 25.6 18.4
PVD 44.4 44.5 45.6 38.0
Other cardiacb 35.3 34.9 36.9 33.1
COPD 20.5 21.2 22.2 16.1
GI 10.8 10.7 10.7 9.9
Liver disease 5.3 6.8 7.1 6.8
Dysrhythmia 30.6 31.7 32.3 26.2
Cancer 12.2 12.2 12.8 9.4
Diabetes 63.6 65.3 67.2 53.4
Abbreviations: ASHD, atherosclerotic heart disease; CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular accident/
transient ischemic attack; ESRD, end-stage renal disease; GI, gastrointestinal
bleeding; PVD, peripheral vascular disease.
aValues are percents unless otherwise specified.
bIncludes pericarditis, endocarditis, myocarditis, other complications of heart
disease, heart transplant, heart valve replacement, and cardiac devices.
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incident dialysis cohort with mortality as end point are
displayed in Table 2. Coefficients for all comorbid conditions
are positive, meaning that all conditions were associated with
shorter survival and are significant predictors. Weights were
assigned to each comorbid condition as follows: a weight of 1
was assigned to ASHD and diabetes; 2 to CVA/TIA, PVD,
COPD, gastro-intestinal bleeding (GI), dysrhythmia, other
cardiac disease, liver disease, and cancer; and 3 to CHF. The
comorbidity score for each patient was defined as the sum of
the weights based on presence or absence of the conditions.
For example, for a patient with diabetes and CHF, and no
other comorbid conditions, the comorbidity score would be
1 (diabetes)þ 3 (CHF)¼ 4. For a patient with ASHD, PVD,
GI bleeding, and CHF, the comorbidity score would be 1
(ASHD)þ 2 (PVD)þ 2 (GI)þ 3 (CHF)¼ 8. The comorbid-
ity score distribution is displayed in Table 3 and Figure 1
(1999 cohort only; results were similar for the
other cohorts). As with individual comorbid conditions,
Table 2 | Parameter estimates from a Cox model for survival analysis using the 2000 US incident dialysis cohort
Variable Coefficient estimates s.e. Relative risk (95% CI) P-value Weighta
Age group, years
0–19 1.1560 0.2248 0.315 (0.203–0.489) o0.0001
20–29 1.5569 0.0979 0.211 (0.174–0.255) o0.0001
30–39 1.1940 0.0535 0.303 (0.273–0.336) o0.0001
40–49 0.9646 0.0352 0.381 (0.356–0.408) o0.0001
50–59 0.8238 0.0280 0.439 (0.415–0.464) o0.0001
60–64 0.6663 0.0303 0.514 (0.484–0.545) o0.0001
65–69 0.5770 0.0248 0.562 (0.535–0.590) o0.0001
70–79 0.3712 0.0196 0.690 (0.664–0.717) o0.0001
X80b 0.0000 0.0000 1.000 NA
Sex
Menb 0.0000 0.0000 1.000 NA
Women 0.0137 0.0144 0.986 (0.959–1.015) 0.3421
Race
Whiteb 0.0000 0.0000 1.000 NA
Asian/Pacific Islander 0.3242 0.0482 0.723 (0.658–0.795) o0.0001
African American 0.2141 0.0170 0.807 (0.781–0.835) o0.0001
Native American 0.2098 0.0616 0.811 (0.719–0.915) 0.0007
Other 0.1945 0.0778 0.823 (0.707–0.959) 0.0124
ESRD primary cause
Diabetes 0.2900 0.0322 1.336 (1.255–1.423) o0.0001 3
Hypertension 0.1862 0.0303 1.205 (1.135–1.278) o0.0001 2
GN/cystic kidney diseaseb 0.0000 0.0000 1.000 NA 0
Other 0.3463 0.0334 1.414 (1.324–1.510) o0.0001 3
Comorbid conditions
ASHD 0.0616 0.0165 1.064 (1.030–1.098) 0.0002 1
CHF 0.2950 0.0164 1.343 (1.301–1.387) o0.0001 3
CVA/TIA 0.1881 0.0159 1.207 (1.170–1.245) o0.0001 2
PVD 0.1990 0.0149 1.220 (1.185–1.256) o0.0001 2
Other cardiac 0.1559 0.0154 1.169 (1.134–1.205) o0.0001 2
COPD 0.2333 0.0167 1.263 (1.222–1.305) o0.0001 2
GI 0.1794 0.0216 1.196 (1.147–1.248) o0.0001 2
Liver disease 0.1885 0.0270 1.207 (1.145–1.273) o0.0001 2
Dysrhythmia 0.2090 0.0158 1.232 (1.195–1.271) o0.0001 2
Cancer 0.2020 0.0205 1.224 (1.176–1.274) o0.0001 2
Diabetes 0.1250 0.0205 1.133 (1.088–1.180) o0.0001 1
Abbreviations: ASHD, atherosclerotic heart disease; CI, confidence interval; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA/TIA,
cerebrovascular accident/transient ischemic attack; ESRD, end-stage renal disease; GI, gastrointestinal bleeding; GN, glomerulonephritis; PVD, peripheral vascular disease.
aWeight assigned to ESRD primary cause and comorbid conditions: 0 for coefficient o0.05, 1 for 0.05 to o0.15, 2 for 0.15 to o0.25, and 3 for X0.25.
bReference group.
Table 3 | Comorbidity score distribution for the four cohorts:
1999, 2000, 2001 incident dialysis patients and 2000
prevalent dialysis patients
Cohort
1999
Incident
2000
Incident
2001
Incident
2000
Prevalent
Score
Mean 6.4 6.6 6.7 5.4
Median 6.0 6.0 7.0 5.0
s.d. 4.1 4.1 4.1 4.1
Minimum 0.0 0.0 0.0 0.0
Maximum 19.0 21.0 21.0 21.0
Score groups, %
0 6.47 6.48 5.65 12.74
1–2 13.26 12.83 12.42 16.53
3–4 16.31 15.44 15.22 17.27
5–7 24.74 25.05 24.50 23.07
8–10 20.41 20.13 21.27 16.72
11–15 17.79 18.97 19.62 12.96
415 1.02 1.08 1.32 0.72
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comorbidity scores increased over time for the incident
cohorts (Po0.0001), and scores were lower for prevalent
than for incident patients (Po0.0001).
Figure 2 presents survival curves for the patient groups
with comorbidity scores in the intervals p3, 4–6, 7–9, and
X10 for each cohort. Patients in lower-score groups survived
longer. Log rank test shows that the four curves are different
(Po0.0001 for all cohorts). The relative risks for the 4–6, 7–9,
and X10 groups relative to p3 group are 1.533, 2.117, and
3.138, respectively, for the 1999 cohort, and similar for the
other cohorts. These numbers indicate that the comorbidity
score is an important predictor for survival.
We also defined the index including comorbid conditions
and ESRD primary cause based on the same model. We
assigned a weight to each ESRD primary cause in the same
way as for comorbid conditions. A weight of 2 was therefore
assigned to hypertension, and 3 to diabetes and other causes
(Table 2). Glomerulonephritis/cystic kidney disease was used
as the reference in the Cox model, and assigned a weight of 0.
Scores for each patient are calculated in the same way as in
the index without ESRD cause. For example, the comorbidity
score for a patient with diabetes and CHF as comorbid
conditions and diabetes as primary ESRD cause would be 1
(diabetes as comorbid condition)þ 3 (CHF)þ 3 (diabetes as
primary ESRD cause)¼ 7.
Comorbidity index validation
Table 4 displays the model fit statistics, predictive ability
statistics, and parameter estimates for all variables in the
model not used for the indexes, from a model with 11
individual comorbid conditions and models with two indexes
for the 1999 incident cohort. A positive percent change value
means that the corresponding statistic has a higher value
from the comorbidity score model than from the individual
comorbid condition model. Otherwise, the statistic has a
lower value from the comorbidity score model. Although
some changes are statistically significant because of the large
sample size, Table 4 shows that the model with the new
comorbidity index without ESRD primary cause was almost
identical in value to the model with 11 individual comorbid
conditions regarding model fit, model predictive ability,
comorbidity predictive ability, and relative risk estimates for
all variables. Except for diabetes as ESRD primary cause and
age groups 0–19, 50–59, and 60–64 years, changes in relative
risk estimates across models for all variables are less than 1%.
The importance of the magnitude of change is subjective, but
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Figure 1 |Percent of patients with each comorbidity score,
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Figure 2 | Survival curves for patient groups with comorbidity scores in the intervals p3, 4–6, 7–9, and X10 for each cohort.
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we consider less than 5% an acceptable change. Findings are
similar for the 2001 incident cohort and 2000 prevalent
cohort (data not shown). Standard errors for all parameter
estimates were also compared across models (data not
shown). They are almost identical. The comorbidity index
including ESRD primary cause also works well, but not as
well as the version excluding it. The new index also works
well for hospitalization and medical cost analyses (Table 5).
The percent change in relative risk and relative cost are less
than two for most variables. The differences in R2 are small,
but the percent changes are large because of the small values
of R2.
Regarding model fit (2 log likelihood, AIC [Akaike’s
information criterion], and SBC [Schwartz Bayesian criter-
ion]), model predictive ability (c-statistic), and the predictive
ability of comorbid conditions (marginal and partial R2), the
11 comorbid conditions in the new comorbidity index and
the 17 comorbid conditions in the CCI are almost identical
(Table 6, 1999 incident cohort). Regarding predictive ability
and the effect on relative risk estimate, the new index works
as well as the 11 individual comorbid conditions (Table 6).
The model fit and the predictive ability of the model with
CCI, which includes CCI and the other variables, is similar to
the model with the 17 individual comorbid conditions.
However, the R2, which measure the predictive ability of CCI
alone, are much lower than the R2 for the 17 individual
comorbid conditions (marginal R2 0.0642 versus 0.0981,
partial R2 0.0381 versus 0.0549). Also, the effect of CCI on
relative risk estimates for variables not in the index is high
(see the ‘Percent Change’ column for ‘Estimates of relative
Table 4 | Comorbidity index validation: comparing the index with the individual comorbid conditions as a set in a Cox
proportional hazard model, 1999 incident dialysis patients, a validation cohort
Parameter
11 Individual
conditions
Score excluding
ESRD cause
Percent change
(P-value)a
Score including
ESRD cause
Percent change
(P-value)a
Model fit statistics
2 LOG L 438141 438223 0.02 438236 0.02
AIC 438195 438257 0.01 438264 0.02
SBC 438412 438394 0.00 438376 0.01
Model predictive ability
c-Statistic 0.6695 0.6687 0.11 (o0.001) 0.6693 0.02 (o0.001)
Predictive ability of comorbid conditions
Marginal R2 0.1119 0.1072 4.44 0.1096 2.09
Partial R2 0.0543 0.0526 3.17 0.0623 14.81
Relative risks for other variables
Age group, years
0–19 0.220 0.215 1.95 (0.033) 0.212 3.60 (0.010)
20–29 0.196 0.195 0.71 (0.633) 0.194 0.94 (0.210)
30–39 0.285 0.286 0.14 (0.377) 0.288 0.93 (0.123)
40–49 0.329 0.331 0.43 (0.123) 0.335 1.68 (0.007)
50–59 0.404 0.409 1.11 (o0.001) 0.416 2.96 (o0.001)
60–64 0.478 0.483 1.10 (0.010) 0.492 3.01 (o0.001)
65–69 0.545 0.550 0.89 (o0.001) 0.558 2.40 (o0.001)
70–79 0.681 0.685 0.60 (0.013) 0.692 1.52 (o0.001)
X80b 1.000 1.000 NA 1.000 NA
Sex
Menb 1.000 1.000 NA 1.000 NA
Women 1.001 1.000 0.06 (0.463) 1.006 0.47 (0.040)
Race
Whiteb 1.000 1.000 NA 1.000 NA
Asian/Pacific islander 0.702 0.704 0.25 (0.797) 0.707 0.70 (0.140)
African American 0.786 0.790 0.41 (0.007) 0.792 0.75 (0.777)
Native American 0.864 0.864 0.07 (0.413) 0.875 1.24 (o0.001)
Other 1.145 1.142 0.25 (0.530) 1.152 0.57 (0.287)
ESRD primary cause
Diabetes 1.292 1.361 5.27 (o0.001)
Hypertension 1.193 1.199 0.52 (0.133)
Glomerulonephritis/cystic renal diseaseb 1.000 1.000 NA
Other 1.267 1.275 0.64 (0.034)
Abbreviations: AIC, Akaike’s information criterion; ESRD, end-stage renal disease; SBC, Schwartz Bayesian criterion.
aPercent change of parameter estimate from the model with comorbidity score relative to estimate from model with individual comorbid conditions. P-value from the
bootstrap method.
bReference group.
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Table 5 | Parameters from the model compared with individual comorbid conditions and with comorbidity score for
hospitalization and medical cost, 2000 incident dialysis patients
First hospitalization Multiple hospitalizations
Parameter
Model with
individual
comorbidities
Model with
comorbidity
score
Percent
change
(P-value)a
Model with
individual
comorbidities
Model with
comorbidity
score
Percent
change
(P-value)a
R2
Marginal 0.0628 0.0563 10.32
Partial 0.0546 0.0491 10.07
Estimates for variables not in the indexb
Age group, years
0–19 1.772 1.795 1.32 1.894 1.919 1.32
20–29 1.081 1.094 1.20 1.361 1.381 1.51
30–39 1.072 1.080 0.80 1.295 1.315 1.52
40–49 0.970 0.981 1.16 1.231 1.255 1.98
50–59 0.958 0.964 0.62 1.029 1.044 1.45
60–64 0.882 0.891 1.03 0.942 0.954 1.25
65–69 0.880 0.891 1.27 0.947 0.961 1.49
70–79 0.897 0.902 0.61 0.927 0.934 0.71
X80c 1.000 1.000 NA 1.000 1.000 NA
Sex
Menc 1.000 1.000 NA 1.000 1.000 NA
Women 1.153 1.160 0.67 1.138 1.144 0.57
Race
Whitec 1.000 1.000 NA 1.000 1.000 NA
Asian/Pacific Islander 0.855 0.860 0.51 0.854 0.856 0.28
African American 0.992 0.990 0.16 1.055 1.051 0.37
Native American 0.984 0.981 0.28 0.977 0.969 0.78
Other 1.034 1.050 1.54 1.100 1.102 0.21
ESRD primary cause
Diabetes 1.108 1.150 3.84 1.184 1.208 2.00
Hypertension 1.026 1.032 0.62 1.080 1.084 0.40
Glomerulonephritis/
cystic renal diseasec
1.000 1.000 NA 1.000 1.000 NA
Other 1.134 1.132 0.18 1.143 1.144 0.04
Hospitalization
days Medical cost
R2
Marginal 0.0300 0.0128 57.39 0.1033 0.0903 12.56
Partial 0.0198 0.0159 19.94 0.0745 0.0686 7.93
Estimates for variables not in modelb
Age group, years 1.000 1.000 0.00 1.000 1.000 0.00
0–19 1.780 1.796 0.92 0.896 0.904 0.82
20–29 1.048 1.066 1.68 0.880 0.891 1.28
30–39 1.059 1.077 1.67 0.910 0.921 1.23
40–49 1.098 1.121 2.09 0.940 0.951 1.21
50–59 1.002 1.018 1.62 0.956 0.963 0.75
60–64 0.949 0.964 1.53 0.958 0.965 0.73
65–69 0.960 0.974 1.53 0.948 0.955 0.70
70–79 0.938 0.946 0.82 0.970 0.973 0.37
X80c 1.000 1.000 NA 1.000 1.000 NA
Sex 1.000 1.000 0.00 1.000 1.000 0.00
Menc 1.000 1.000 NA 1.000 1.000 NA
Women 1.161 1.170 0.72 1.073 1.076 0.29
Race
Whitec 1.000 1.000 NA 1.000 1.000 NA
Asian/Pacific Islander 0.900 0.904 0.45 1.026 1.031 0.49
African American 1.082 1.082 0.04 1.100 1.107 0.58
Table 5 continued on the following page
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Table 5 | Continued
First hospitalization Multiple hospitalizations
Parameter
Model with
individual
comorbidities
Model with
comorbidity
score
Percent
change
(P-value)a
Model with
individual
comorbidities
Model with
comorbidity
score
Percent
change
(P-value)a
Native American 0.921 0.919 0.25 0.957 0.959 0.19
Other 1.071 1.078 0.59 1.037 1.043 0.56
ESRD primary cause
Diabetes 1.231 1.303 5.80 1.109 1.150 3.69
Hypertension 1.060 1.070 0.87 1.012 1.014 0.27
Glomerulonephritis/
cystic renal diseasec
1.000 1.000 NA 1.000 1.000 NA
Other 1.188 1.193 0.43 1.020 1.027 0.72
Abbreviations: ESRD, end-stage renal disease.
aPercent change of parameter estimate from the model with comorbidity score relative to estimate from model with individual comorbid conditions.
bThe parameters corresponding to these variables are relative risk for hospitalization and times of increment for medical cost.
cReference group.
Table 6 | Comparison between new comorbidity score and Charlson Comorbidity Index, 1999 incident dialysis patients,
a validation cohort
Model Model
11 Individual
comorbid conditions
New index
score
Percent change
(P-value)a
17 Individual
comorbid conditions
Charlson
score
Percent change
(P-value)a
Model fit statistics
2 LOG L 438186 438247 0.01 438024 438804 0.18
AIC 438240 438281 0.01 438090 438838 0.17
SBC 438456 438418 0.01 438355 438975 0.14
Model predictive ability
c-Statistic 0.6691 0.6685 0.09 0.6709 0.6623 1.30
Predictive ability of comorbid conditions
Marginal R2 0.1007 0.0957 5.22 0.0981 0.0642 52.85
Partial R2 0.0524 0.0511 2.56 0.0549 0.0381 44.00
Estimates of relative risks for variables not in the Index
Age group, years
0–19 0.201 0.200 0.65 0.186 0.177 4.69
20–29 0.182 0.181 0.76 0.178 0.166 6.95
30–39 0.269 0.269 0.14 0.266 0.244 8.43
40–49 0.316 0.317 0.31 0.312 0.289 7.30
50–59 0.398 0.400 0.63 0.393 0.369 5.92
60–64 0.474 0.478 0.68 0.468 0.443 5.34
65–69 0.543 0.547 0.69 0.541 0.521 3.73
70–79 0.682 0.684 0.30 0.678 0.663 2.18
X80b 1.000 1.000 NA 1.000 1.000 NA
Sex
Menb 1.000 1.000 NA 1.000 1.000 NA
Women 0.991 0.991 0.05 0.994 0.992 0.26
Race
Whiteb 1.000 1.000 NA 1.000 1.000 NA
Asian/Pacific Islander 0.691 0.690 0.15 0.699 0.684 2.14
African American 0.776 0.776 0.07 0.765 0.765 0.03
Native American 0.867 0.863 0.44 0.861 0.831 3.49
Other 1.138 1.136 0.12 1.134 1.116 1.64
ESRD primary cause
Diabetes 1.367 1.409 3.08 1.323 1.223 7.59
Hypertension 1.224 1.231 0.57 1.215 1.242 2.27
Glomerulonephritis/
cystic renal diseaseb
1.000 1.000 NA 1.000 1.000 NA
Other 1.275 1.280 0.39 1.262 1.258 0.31
Abbreviations: AIC, Akaike’s information criterion; ESRD, end-stage renal disease; SBC, Schwartz Bayesian criterion.
aPercent change of parameter estimate from the model with comorbidity score relative to estimate from model with individual comorbidities.
bReference group.
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risks for variables not in the Index’ in Table 6). Results for the
2000 and 2001 incident and 2000 prevalent cohorts are
almost identical.
DISCUSSION
A useful comorbidity index should be simple and validated
for specific use as a substitute for individual comorbid
conditions. In this study, a new comorbidity index, including
and excluding ESRD primary cause, was developed for
survival analysis of dialysis patients and validated as a
predictor and an adjuster for replacing the individual
comorbid conditions. The new index performs well in
analyses for mortality, hospitalization, and medical costs in
both incident and prevalent cohorts. It also outperforms the
CCI in both predictive ability and inference. This comorbid-
ity index can be used for the comparison of comorbidity
burden and comorbidity burden change over a fixed period,
reflecting quality of care, among dialysis facilities; standard
mortality ratio calculation; and outcome analysis that
requires adjustment for comorbid conditions. Use of the
index will make the comparisons easier, the computations
simpler, and the estimates of effects more stable.
The ESRD Medical Evidence Report (form CMS-2728)
lists eight categories of primary ESRD causes: diabetes,
hypertension, glomerulonephritis, cystic renal disease, other
urologic disease, unknown cause, other cause, and missing.
We began by using these eight categories. Because the effect
of cystic renal disease is similar to that of glomerulonephritis,
we combined these two categories into one. For the same
reason, we combined ‘other urologic disease,’ ‘unknown
cause,’ and ‘other cause’ into a category called ‘other.’ Because
the missing-cause group was too small for a significant
comparison with the other causes, we grouped it with ‘other.’
The effect of diabetes looks smaller than expected because
diabetes was the primary cause of ESRD for most of the
diabetic patients, and diabetes as ESRD primary cause, which
has a high score, is also in the model. Thus, most diabetes
patients actually receive a high score, 4 (3 from diabetes as
primary cause of ESRD and 1 from diabetes as a comorbid
condition), for diabetes.
Age was not included in our comorbidity index because
the effects of age and comorbid conditions were at very
different levels (see coefficient estimates in Table 2), and this
difference makes assigning definite scores difficult. Also, age
affects mortality, hospitalization, and medical costs differ-
ently. An index including age developed for mortality would
be difficult to generalize to hospitalization and medical cost
analyses. But, because age, comorbid conditions, and ESRD
primary cause are highly correlated, age and ESRD primary
cause should be included in the model when the comorbidity
index excluding ESRD primary cause is used, and age should
be included when the index including ESRD primary cause is
used.
Patients who returned to dialysis after failed transplants
were included in the validation using the 2000 prevalent
cohort. Neither adding previous transplant as an indicator in
the model nor excluding those patients from the model
changes the validation result. This might be because these
patients were not considerably different from the other
patients, or because this is a small subgroup of the prevalent
dialysis cohort (about 8%), or both.
Another comorbidity index, the Index of Coexistent
Disease (ICED), also works better than the CCI in analyses
of ESRD patients.16 The ICED includes a patient physical
functioning component, which might improve its perfor-
mance. However, the ICED is difficult to use.17,18 The score
given is based not only on the presence or absence of the
specific diseases and physical functions, but also on the
severity of diseases or physical impairment. Assigning scores
at the start of a study requires trained personnel. This is
impractical for many studies, especially for studies based on
administrative data. A useful comorbidity index should work
well, be easy to use, and thus become widely used.
The new comorbidity index proposed in this study
was designated for analyses using administrative data. The
accuracy of the comorbid conditions documented in the data
may affect the performance of the index. We provide the
International Classifications of Diseases, Ninth Edition,
Clinical Modification (ICD-9 CM) codes and Current
Procedural Terminology codes used for defining comorbid
conditions from claims in the Appendix. If different codes are
used for comorbid condition definitions, the scores for the
conditions defined in this study may not be applicable.
Information on the comorbid conditions included in this
index was collected from both the Medical Evidence Report
and claims over a 6-month entry period. The index cannot
be used for studies that evaluate outcomes in the entry
period. The index was developed based on the national
cohort of Medicare dialysis patients and is not validated for
non-Medicare patients. It should be used with caution when
non-Medicare patients are included in the study. Both
hemodialysis and peritoneal dialysis cohorts were included
in score development and evaluation. Separate validations
were performed for hemodialysis and peritoneal dialysis
patients, with good results. However, because of the small
sample size of the peritoneal dialysis cohort, validation may
not be reliable, and the score should be applied with caution
to peritoneal dialysis patients.
MATERIALS AND METHODS
Study population and data source
This study included all US patients who developed ESRD in 1999,
2000, and 2001; survived at least 9 months; used dialysis as renal
replacement therapy; and had Medicare as primary payer with Part
A and Part B coverage at day 91 of ESRD. The first 90 days were
excluded because Medicare information for that period was
incomplete for many patients; months 4–9 were used to define
patient baseline characteristics. Patients who underwent transplant,
were lost to follow-up, or changed primary payer during the baseline
period were excluded. Patients who were HIV positive, had AIDS
during the baseline period, or died of AIDS in the follow-up period
were also excluded. Patients were followed from the first day
after the baseline period until the date of death, transplant, loss to
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follow-up, change of primary payer, or end of 2005. The 2000
incident cohort was used as the training population and the 1999
and 2001 incident cohorts, separately, as the testing populations.
The 2000 point prevalent dialysis patients (on dialysis on 1 January
2000) who survived at least 6 months in 2000 and had Medicare as
primary payer with Part A and Part B coverage on 1 January 2000,
were also used as a testing population. The first 6 months (1 January
2000, to 30 June 2000) were used to define patient baseline
characteristics, and the same exclusion criteria were applied.
Data were from the CMS Renal Management Information
System (REMIS) and CMS Standard Analytical Files. The REMIS
database includes information from the CMS Medicare Enrollment
Database, the United Network for Organ Sharing transplant
database, the ESRD Medical Evidence Report (form CMS-2728),
and the ESRD Death Notification (form CMS-2746). The Standard
Analytical Files include Medicare Part A institutional claims and
Part B physician/supplier claims. Patient demographic information,
including age, sex, race (white, African American, Native American,
Asian, and other); ESRD primary cause (diabetes, hypertension,
glomerulonephritis/cystic renal disease, and other); and date of
death were obtained from the REMIS database. Patient comorbid
conditions, hospitalization dates, and medical costs were derived
from CMS claim files.
Comorbidity and outcomes
The new comorbidity index was defined by 11 comorbid conditions
used by the USRDS,15 most of which are listed in the Medical
Evidence Report. The conditions are diabetes, ASHD, CHF, PVD,
CVA/TIA, dysrhythmia, other cardiac diseases (including pericardi-
tis, endocarditis, myocarditis, other complications of heart disease,
heart transplant, heart valve replacement, and cardiac devices),
cancer, liver disease, GI bleeding, and COPD. Liver disease and GI
bleeding are not included on the Medical Evidence Report. A patient
is defined as having a comorbid condition if a code for it can be
found on the Medical Evidence Report or in claims during the
6-month baseline period. Comorbid conditions from claims were
defined using ICD-9 CM codes. The ICD-9 CM diagnosis codes
and V codes defining the conditions were designated by the
USRDS,15 and are listed in the Appendix. The method used to
define comorbid conditions from claims has been previously
described.19 Claims over 6 months were used for defining comorbid
conditions because the Medical Evidence Report may underestimate
patient comorbid conditions and the most recent claims supply
supplemental and updated information, especially for prevalent
patients.
The outcome used to develop and test the index was death. We
also examined whether the index could be used for hospitalization
(first hospitalization, multiple hospitalizations, and hospital days)
and medical cost analyses. Data on death were obtained from the
ESRD Death Notification (form CMS-2746). Hospitalization data in
the follow-up period were derived from the Medicare Part A
inpatient claims. Per-patient per-month Medicare allowable costs in
the follow-up period were calculated from both Part A and Part B
claims. Institutional Medicare allowable expenditures include
Medicare payment, coinsurance, deductibles, and any payment
provided by a payer other than Medicare. Dollar amounts during the
follow-up period were assembled and were linearly prorated for
claims that spanned the beginning or end of the follow-up period.
Expenditures in dollars were summed for each patient and divided
by the number of follow-up months to arrive at the per-patient per-
month expenditure.
Development and validation of the index
A Cox proportional regression model was fitted for the 2000 incident
dialysis cohort with time to death as the response variable and age,
race, sex, primary ESRD cause, and the 11 comorbid conditions as
covariates. Categorical age was used with nine age groups (ages 0–19,
20–29, 30–39, 40–49, 50–59, 60–64, 65–69, 70–79, and X80 years). A
Cox proportional regression model can be expressed as
lðtjx1x2; . . . ; xkÞ ¼ l0ðtÞexpðb1x1þb2x2þ . . .þbkxkÞ;
where x1, x2,y, and xk are covariates; l(t|x1, x2,y, xk) is the hazard
at time t given x1, x2,y, xk; l0(t) is the baseline hazard at time t
corresponding to x1 ¼ 0, x2 ¼ 0,y, xk¼ 0; b1, b2,,y, and bk, are
coefficients of x1, x2,y, and xk, and exp(b1), exp(b2), y, and
exp(bk) are the relative risk of x1, x2,y, and xk. Another expression
of a Cox proportional regression model is
Sðtjx1; x2; . . . ; xkÞ ¼ ½S0ðtÞexpðb1x1þb2x2þ . . .þbkxkÞ;
where S(t|x1, x2,y, xk) is the survival probability at time t given x1,
x2,y, xk and S0(t) is the baseline survival probability at time t
corresponding to x1 ¼ 0, x2 ¼ 0, y, xk¼ 0.
After the coefficients b1, b2,,y, and bk, were estimated using the
2000 incident cohort, an integer weight was assigned to each comorbid
condition as follows: 0 for coefficiento0.05, 1 for 0.05 too0.15, 2 for
0.15 too0.25, and 3 forX0.25. To maintain the linear relationship of
comorbidity score and log hazard in the Cox model, coefficients, not
relative risks, were used to assign weights. The comorbidity score for
each patient was the sum of the weights based on the presence or
absence of the conditions. Specifically, weights are w1, w2,y,w11, for
the 11 conditions, respectively; for a patient with conditions 1 and 5
only, the comorbidity score would be w1þw5. For a patient with
conditions 3, 5, 8, and 9, the comorbidity score would be
w3þw5þw8þw9. The comorbidity score is used as a continuous
covariate in models for outcome analyses.
The index was validated using the 1999 and 2001 US incident
dialysis cohorts and the 2000 US prevalent dialysis cohort,
separately. Model fit statistics (2 times log likelihood, AIC and
SBC), model predictive ability statistic (c-statistic for time-to-event
data), and the parameter estimates for the variables not included in
the score and their s.e. were compared between the model using
comorbidity score and the model using individual comorbid
conditions. The 2 times log likelihood can be used to compare
model fit. A smaller value means a higher probability of the
observed values being observed. Therefore, the smaller the 2 times
log likelihood, the better the model. The c-statistic is used to
measure to what extent predicted values from the model are
concordant with observed values, that is, whether a pair of observed
values occurs in the same order as their predicted values. It was used
to measure the model predictive ability; the higher the c-statistic, the
better the model. The predictive abilities of comorbidity scores and
the individual comorbid conditions as a set were also compared
using the Kent-O’Quigley R2 as an indicator.20 Similar to the R2 for
a linear regression model, the Kent-O’Quigley R2 can be used to
check how much of the data ‘variation’ can be explained by specific
variables. The differences in c-statistic and estimates of variables not
in the index between the model using individual comorbid
conditions and the model using indexes were tested using the
bootstrap method. Checking usability of the index for hospitaliza-
tion and medical cost analyses was done similarly using the 2000
incident data. Cox proportional regression models, Andersen–Gill
models, Poisson regression models, and linear regression models
were used for first hospitalization, multiple hospitalizations, hospital
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days, and medical cost analyses, respectively. The cost analysis was
based on logged scale of per-patient per-month expenditures
because of the skewness of expenditure data.
A comorbidity index including ESRD primary cause was
also developed for survival analysis based on the same model,
using the 2000 incident dialysis cohort, and validated using the 1999
and 2001 US incident dialysis cohorts and 2000 prevalent dialysis
cohort in the same way as for the index without ESRD primary
cause.
The new comorbidity index cannot be compared with the CCI
directly because many of the 17 comorbid conditions the CCI uses
cannot be derived from the Medical Evidence Report (we excluded
renal disease because all patients had renal disease). The 17
comorbid conditions were defined from claims only. To make it
comparable, we redefined our 11 comorbid conditions using claims
only; however, this might lead to underestimates because the
6-month period might not be long enough to yield claims for all
comorbid conditions. We then repeated the procedures described
above and compared the results with results from models using the
CCI. The 17 comorbid conditions used for the CCI were derived
from patient Medicare Part A and Part B claims using the ICD-9 CM
diagnosis codes given by Deyo.21 We compared the changes in the
statistics used for validating the new comorbidity index from the
11-individual-condition model to the new comorbidity index model
and from the 17-individual-condition model to the CCI model for
all four cohorts (1999, 2000, 2001 incident cohorts and 2000
prevalent cohort). SAS version 9.1 (SAS Institute, Cary, NC, USA)
was used to perform all analyses in this study.
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International classification of diseases, ninth revision, clinical
modification codes (ICD-9-CM) used for defining the 13
comorbid conditions for the new comorbidity index
Comorbid condition
ICD-9-CM diagnosis
codes
ICD-9-CM V
codes
Atherosclerotic heart
disease
410–414 V45.81;
V45.82
Congestive heart failure 398.91; 422; 425; 428; 402.X1;
404.x1; 404.x3
V42.1
Cerebrovascular accident/
transient ischemic attack
430–438
Peripheral vascular disease 40–444; 447; 451–453; 557
Other cardiac 420–421; 423–424; 429;
785.0–785.3
V42.2;V43.3
Chronic obstructive
pulmonary disease
491–494; 496; 510
Gastrointestinal bleeding 456.0–456.2; 530.7; 531–534;
569.84; 569.85; 578
Liver disease 570; 571; 572.1; 572.4;
573.1–573.3
V42.7
Dysrhythmia 426–427 V45.0; V53.3
Cancer 140–172; 174–208; 230–231;
233–234
Diabetes 250; 357.2; 362.0x; 366.41
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